Figure 4.

RT+CpG+OX40 Modifies Gene Expression in TME for Favorable Anti-Tumor Response. Fold-change gene expression of (A–D) chemokines, (E–H) type I IFN pathway genes, (I–L) acute phase inflammatory cytokines, and (M–P) cell adhesion and immune activation genes in the B78 model on day 14 following treatment initiation with PBS (black), RT (blue), CpG+OX40 (red), and RT+CpG+OX40 (teal). Results are presented from a single set of qPCR analyses that were run simultaneously on tumor tissue samples collected from two independent experiments (n=7-10 total per group). For each gene of interest, significance was determined by Kruskal-Wallis testing; if significance was found groups were compared via a Dunn test and adjusted using the Holm method. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.